| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Radiation Epidemiology Branch, Epidemiology and Biostatistics Program, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland 20892 [R. E. C., J. D. B.], Harvard Medical School, Boston, Massachusetts 02115 [W. C. M.], Cancer Statistics Branch, Surveillance Program, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland 20892 [L. G. R.], and Connecticut Tumor Registry, Department of Health Services, Hartford, Connecticut 06106 [J. T. F.]
Leukemia following chemotherapy for breast cancer was studied among patients diagnosed during 1973–1985 within the population-based tumor registries in the Surveillance, Epidemiology, and End Results Program. Among 13,734 women given initial chemotherapy, 24 developed acute nonlymphocytic leukemia (ANLL) compared to 2.1 expected based on general population rates (observed/expected = 11.5; 95% confidence interval = 7.4–17.1). Overall, 58 excess ANLL occurred per 100,000 women-years at risk for patients treated with chemotherapy. The cumulative incidence was 0.7% at 10 years. Risk remained high over all periods of observation up to 9 years after treatment. Among 7974 women treated only with surgery during 1973 and 1974, a period before the widespread use of adjuvant chemotherapy for breast cancer, ANLL was not significantly increased (observed = 7, expected = 5.1). A case-control study was then conducted in Connecticut to evaluate in more detail the risk associated with adjuvant chemotherapy in the general population. Among 20 cases (17 incident leukemias and 3 deaths due to preleukemia) and 60 matched controls, alkylating agents were linked to an 11.9-fold risk of ANLL and preleukemia (95% confidence interval = 2.6–55). Chemotherapy regimens including melphalan were related to a higher risk of leukemic conditions than those including cyclophosphamide.
These data suggest that women in the general population treated with adjuvant chemotherapy for breast cancer are at an increased risk of leukemia, that the risk remains high among long-term survivors, and that risk differs by type of alkylating agent administered.
1 To whom requests for reprints should be addressed, at Executive Plaza North, Suite 408, National Cancer Institute, Bethesda, MD 20892.
Received 8/ 4/89.
Revised 1/ 4/90.
This article has been cited by other articles:
|
|
 |
|
  C. Bastianutto, A. Mian, J. Symes, J. Mocanu, N. Alajez, G. Sleep, W. Shi, A. Keating, M. Crump, M. Gospodarowicz, et al. Local Radiotherapy Induces Homing of Hematopoietic Stem Cells to the Irradiated Bone Marrow Cancer Res., November 1, 2007; 67(21): 10112 - 10116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. R. Rozados, A. M. Sanchez, S. I. Gervasoni, H. H. Berra, P. Matar, and O. Graciela Scharovsky Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity Ann. Onc., October 1, 2004; 15(10): 1543 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kroger, A. R. Zander, G. Martinelli, P. Ferrante, J. M. Moraleda, G. A. Da Prada, T. Demirer, G. Socie, and G. Rosti Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation Ann. Onc., April 1, 2003; 14(4): 554 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Smith, J. Bryant, A. DeCillis, and S. Anderson Acute Myeloid Leukemia and Myelodysplastic Syndrome After Doxorubicin-Cyclophosphamide Adjuvant Therapy for Operable Breast Cancer: The National Surgical Adjuvant Breast and Bowel Project Experience J. Clin. Oncol., April 1, 2003; 21(7): 1195 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. N. Hortobagyi Adjuvant Systemic Therapy for Early Breast Cancer: Progress and Controversies Clin. Cancer Res., July 1, 2001; 7(7): 1839 - 1842. [Full Text] [PDF]
|
|
|
|
 |
|
 B. J.S. Sanderson, K. J. Johnson, and W.D. Henner Induction of mutant lymphocytes in cyclophosphamide- and chlorambucil-treated patients Mutagenesis, May 1, 2001; 16(3): 197 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Braun, G. Schlimok, I. Heumos, G. Schaller, L. Riethdorf, G. Riethmüller, and K. Pantel erbB2 Overexpression on Occult Metastatic Cells in Bone Marrow Predicts Poor Clinical Outcome of Stage I-III Breast Cancer Patients Cancer Res., March 1, 2001; 61(5): 1890 - 1895. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. Smith, L. Rubinstein, J. R. Anderson, D. Arthur, P. J. Catalano, B. Freidlin, R. Heyn, A. Khayat, M. Krailo, V. J. Land, et al. Secondary Leukemia or Myelodysplastic Syndrome After Treatment With Epipodophyllotoxins J. Clin. Oncol., February 1, 1999; 17(2): 569 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Saltz and N. E. Kemeny Adjuvant Chemotherapy of Colorectal Cancer Oncologist, February 1, 1996; 1(1): 22 - 29. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
